Drug-Device Combinations Global Markets

Dallas, TX -- (SBWIRE) -- 01/09/2013 -- ReportsnReports.com adds “Global Markets for Drug-Device Combinations ” new market research report to its store. This report provides:
- An overview of the global market for drug-device combinations
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Detailed coverage of such product categories as drug-eluting stents (DES), drug-eluting beads (DEB), antimicrobial catheters, antibiotic-loaded bone cements, glass ionomer cements, bone graft substitutes, antibacterial-releasing dental-restorative materials, biologic wound-care products such as collagen-based dressings as therapeutic agents for wound-healing, drug-device combination products for ocular applications, and photodynamic therapy
- Identification of current and future technologies, products, market segments/end markets, and government and regulatory agencies
- Discussion of participating companies in light of technological strengths and weaknesses, relative market shares, marketing strengths, and innovative marketing practices
- Detailed patent analysis and research and development updates
- Comprehensive company profiles of major players.

STUDY GOALS AND OBJECTIVES
This report analyzes the market for drug-device combination products. It provides descriptions of technologies and products, a review of the status of research and development (R&D) initiatives and a forecast of market revenues through 2017. Company profiles, clinical trials, and a patent analysis are provided as well.

Example product categories that are covered include:
- Drug-eluting stents (DES).
- Drug-eluting beads (DEB).
- Transdermal patches.
- Antimicrobial catheters.
- Antibiotic-loaded bone cements.
- Glass ionomer cements.
- Bone graft substitutes.
- Antibacterial-releasing dental restorative materials.
- Biologic wound care products, such as collagen-based dressings as therapeutic agents for wound healing.
- Drug-device combination products for ocular applications.
- Photodynamic therapy.

THE IMPORTANCE OF THIS STUDY
Products that combine a drug or biologic with a device, such as drug-eluting stents and drug-delivery systems, can offer valuable approaches for treating diseases. In addition, developments in cell-based therapeutics, progenitor cell exploitation, growth factor delivery and advanced formulation strategies are becoming the basis of even more advanced combination device strategies. Technology advancements in the drug-device combination market have been of considerable importance in recent years, and the pace of activity seems to be quickening with the appearance of many development-stage companies.

Since the approval of Johnson & Johnson's Cypher drug-eluting stent in 2003 and Boston Scientific's Taxus drug-eluting stent in 2004, drug-device combination products have attracted significant medical and media attention. But combination products are subject to intense regulatory scrutiny for safety and effectiveness. Teams of device and drug product reviewers at a number of Food and Drug Administration (FDA) centers are dedicated to evaluating such products. Thus, the bar is very high for FDA product approvals, and consequently combination products in certain categories are very small in number. For example, the entire fibrin sealant market is shared by a handful of FDA-approved products such as TachoSil, the first absorbable fibrin sealant patch for use in cardiovascular surgery. Beyond drug-eluting stents and other categories noted above, combination products subject to FDA scrutiny include innovative drug-delivery systems, hemostatic sealants, photodynamic-therapy systems, gene-therapy systems, and products for many other investigational treatments.

The development of the market for combination products is closely related to another dynamic and fast growing healthcare segment generally termed “drug-delivery systems”. “Delivery systems” represents a vast area of research, and development within biomaterials and medicine and the demand for sophisticated drug-delivery devices is behind many novel product developments. Advanced drug-delivery devices offer increased efficiency, improved performance and convenience.

SCOPE AND FORMAT
In preparing this report, an overall study of the drug-device combination market was undertaken.
The report covers the following product categories:
- Drug-eluting stents (DES).
- Drug-eluting beads (DEB).
- Transdermal patches.
- Antimicrobial catheters.
- Antibiotic-loaded bone cements.
- Glass ionomer cements.
- Bone graft substitutes.
- Antibacterial-releasing dental restorative materials.
- Biologic wound care products, such as collagen-based dressings as therapeutic agents for wound healing.
- Drug-device combination products for ocular applications.
- Photodynamic therapy.
- Many nanotechnology applications.

Devices that do not combine a drug with the delivery mechanism are not covered; for example, insulin pumps are not covered.

Related areas, such as drug delivery systems and nanotechnology, were key to the analysis as well, as these newer areas such as nanotechnology foreshadow likely product developments in the years ahead. All major aspects of the drug-device combination market are addressed including identification of current and future technologies, products, market segments/end markets, and government and regulatory involvement. Participating companies are discussed in light of technological strengths and weakness, relative market share, marketing strengths, and innovative marketing practices. Included is a detailed discussion of the current regulatory environment for drug-device combination products and how it is affecting development and approval of such products.

METHODOLOGY AND INFORMATION SOURCES
Data for this study were collected using both primary and secondary data research techniques. A literature search was conducted covering scientific, medical, business and technical documents, as well as patents. Since most segments of the drug-device combination market are not routinely measured via an economic census, BCC derived estimates from a variety of sources. Whenever market estimates are derived, they are fully noted. All forecasts are in current (nominal) dollars, unadjusted for inflation.

Buy your copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=213074 . Alternatively, you can request a sample @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=213074 analyze the report format and sample data before making your final purchase decision.

Contact sales@reportsandreports.com for further information.

Connect US:
Twitter: https://twitter.com/marketsreports
Facebook: http://www.facebook.com/pages/ReportsnReports/191441427571689
Google Plus: https://plus.google.com/u/0/111656568937629536321/posts